| Project name | Core technologies | |
| AD early screening | Neuro-derived exosome blood test, completed research and development, ready to apply for US breakthrough medical device certification | |
| Covid-19 nucleic acid self-test | NuRapid new technology, similar to US Cue Health, declares US EUA as a US company | |
| Pneumonia in children Streptococcus |
Develop home or community testing with NuRapid technology for nucleic acid rapid testing, and plan to apply for US breakthrough medical device certification | |
| New products of exosomes | Exosomal prostate cancer (blood test, urine test) | The product series of tissue-specific exosomes will gradually apply for registration certificates in China, the United States and the European Union. |
| Exosomal bowel cancer | ||
| Exosomal liver cancer | ||
| Exosomal breast cancer | ||
| Exosome lung cancer | ||

Go abroad, enter the United States,
It is the dream and expectation that the Microdiag people have been sticking to for 12 years;
In 5 years, Microdiag entered the first-tier market in the United States and obtained original international recognition and interest premium.